Early immune recovery after autologous transplantation in non-Hodgkin lymphoma patients: predictive factors and clinical significance

References

• Weaver CH, Hazelton B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood. 1995;86:3961–3969.
   PubMed Web of Science ®Google Scholar
• Ketterer N, Salles G, Raba M, et al. High CD34(+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood. 1998;91:3148–3155.
   PubMed Web of Science ®Google Scholar
• Allan DS, Keeney M, Howson-Jan K, et al. Number of viable CD34(+) cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;29:967–972.
   PubMed Web of Science ®Google Scholar
• Nieboer P, de Vries EG, Vellenga E, et al. Factors influencing haematological recovery following high-dose chemotherapy and peripheral stem-cell transplantation for haematological malignancies; 1-year analysis. Eur J Cancer. 2004;40:1199–1207.
   PubMed Web of Science ®Google Scholar
• Russell A, Malik S, Litzow M, et al. Dual roles of autologous CD8 + T cells in hematopoietic progenitor cell mobilization and engraftment. Transfusion. 2015;55:1758–1765.
   PubMed Web of Science ®Google Scholar
• Holtan SG, Porrata LF, Micallef IN, et al. AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma. Clin Lymphoma Myeloma. 2007;7:315–318.
   PubMedGoogle Scholar
• Atta EH, de Azevedo AM, Maiolino A, et al. High CD8 + lymphocyte dose in the autograft predicts early absolute lymphocyte count recovery after peripheral hematopoietic stem cell transplantation. Am J Hematol. 2009;84:21–28.
   PubMed Web of Science ®Google Scholar
• Valtola J, Varmavuo V, Ropponen A, et al. Blood graft cellular composition and posttransplant recovery in non-Hodgkin’s lymphoma patients mobilized with or without plerixafor: a prospective comparison. Transfusion. 2015;55:2358–2368.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Litzow MR, Inwards DJ, et al. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2004;33:291–298.
   PubMed Web of Science ®Google Scholar
• Katipamula R, Porrata LF, Gastineau DA, et al. Apheresis instrument settings influence infused absolute lymphocyte count affecting survival following autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin’s lymphoma: the need to optimize instrument setting and define a lymphocyte collection target. Bone Marrow Transplant. 2006;37:811–817.
   PubMed Web of Science ®Google Scholar
• Yoon DH, Sohn BS, Jang G, et al. Higher infused CD34 + hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin’s lymphoma. Transfusion. 2009;49:1890–1900.
   PubMed Web of Science ®Google Scholar
• Blystad AK, Delabie J, Kvaløy S, et al. Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy. Br J Haematol. 2004;125:605–612.
   PubMed Web of Science ®Google Scholar
• Rutella S, Rumi C, Laurenti L, et al. Immune reconstitution after transplantation of autologous peripheral CD34 + cells: analysis of predictive factors and comparison with unselected progenitor transplants. Br J Haematol. 2000;108:105–115.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Gastineau DA, Padley D, et al. Re-infused autologous graft natural killer cells correlates with absolute lymphocyte count recovery after autologous stem cell transplantation. Leuk Lymphoma. 2003;44:997–1000.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Inwards DJ, Ansell SM, et al. Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. Biol Blood Marrow Transplant. 2008;14:807–816.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Gertz MA, Inwards DJ, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood. 2001;98:579–585.
   PubMed Web of Science ®Google Scholar
• Gordan LN, Sugrue MW, Lynch JW, et al. Correlation of early lymphocyte recovery and progression-free survival after autologous stem-cell transplant in patients with Hodgkin’s and non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2003;31:1009–1013.
   PubMed Web of Science ®Google Scholar
• Joao C, Porrata LF, Inwards DJ, et al. Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma. Bone Marrow Transplant. 2006;37:865–871.
   PubMed Web of Science ®Google Scholar
• Stover DG, Reddy VK, Shyr Y, et al. Long-term impact of prior rituximab therapy and early lymphocyte recovery on auto-SCT outcome for diffuse large B-cell lymphoma. Bone Marrow Transplant. 2012;47:82–87.
   PubMed Web of Science ®Google Scholar
• Kim H, Sohn HJ, Kim SE, et al. Lymphocyte recovery as a positive predictor of prolonged survival after autologous peripheral blood stem cell transplantation in T-cell non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2004;34:43–49.
   PubMed Web of Science ®Google Scholar
• Boulassel MR, Herr AL, deB Edwardes MD, et al. Early lymphocyte recovery following autologous peripheral stem cell transplantation is associated with better survival in younger patients with lymphoproliferative disorders. Hematology. 2006;11:165–170.
   PubMed Web of Science ®Google Scholar
• Tiwari D, Gao F, Hidalgo J, et al. Prognostic significance of early lymphocyte recovery after post-autografting administration of GM-CSF in non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2007;40:671–675.
   PubMed Web of Science ®Google Scholar
• Gratama JW, Kraan J, Keeney M, et al. Validation of the single-platform ISHAGE method for CD34(+) hematopoietic stem and progenitor cell enumeration in an international multicenter study. Cytotherapy. 2003;5:55–65.
   PubMed Web of Science ®Google Scholar
• DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin’s lymphoma. J Clin Oncol. 2009;27:4767–4773.
   PubMed Web of Science ®Google Scholar
• Varmavuo V, Rimpiläinen J, Kuitunen H, et al. Engraftment and outcome after autologous stem cell transplantation in plerixafor-mobilized non-Hodgkin’s lymphoma patients. Transfusion. 2014;54:1243–1250.
   PubMed Web of Science ®Google Scholar
• Moreb JS, Salmasinia D, Hsu J, et al. Long-term outcome after autologous stem cell transplantation with adequate peripheral blood stem cell mobilization using plerixafor and G-CSF in poor mobilizer lymphoma and myeloma patients. Adv Hematol. 2011;517–561.
   Google Scholar
• Varmavuo V, Mäntymaa P, Nousiainen T, et al. Blood graft composition after plerixafor injection in patients with NHL. Eur J Haematol. 2012;89:128–135.
   PubMed Web of Science ®Google Scholar
• Varmavuo V, Mäntymaa P, Kuittinen T, et al. Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin’s lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor. Transfusion. 2012;52:1785–1791.
   PubMed Web of Science ®Google Scholar
• Muraro PA, Robins H, Malhotra S, et al. T cell repertoire following autologous stem cell transplantation for multiple sclerosis. J Clin Invest. 2014;124:1168–1172.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Identifier NCT02570542, Impact of CD34 + cell dose on progression-free survival following high dose therapy and autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma (DLBCL); 2015; [cited 2015 Nov 2]. Available from: https://clinicaltrials.gov/ct2/show/NCT02570542?term=NCT02570542&rank=1
   Google Scholar